Aptose Biosciences (TSE:APS) Posts Earnings Results

Aptose Biosciences (TSE:APSGet Free Report) (NASDAQ:APTO) posted its quarterly earnings data on Thursday. The biotechnology company reported C($2.01) earnings per share (EPS) for the quarter, FiscalAI reports.

Aptose Biosciences Price Performance

APS opened at C$1.99 on Friday. Aptose Biosciences has a twelve month low of C$1.02 and a twelve month high of C$16.50. The firm has a market cap of C$5.08 million, a price-to-earnings ratio of -0.25 and a beta of -0.05. The company has a current ratio of 1.05, a quick ratio of 5.41 and a debt-to-equity ratio of -117.37. The company has a fifty day simple moving average of C$1.74 and a 200 day simple moving average of C$1.91.

Aptose Biosciences Company Profile

(Get Free Report)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

See Also

Earnings History for Aptose Biosciences (TSE:APS)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.